BR112019000282A2 - forma de dosagem oral contendo um revestimento exterior de liberação rápida - Google Patents

forma de dosagem oral contendo um revestimento exterior de liberação rápida

Info

Publication number
BR112019000282A2
BR112019000282A2 BR112019000282-0A BR112019000282A BR112019000282A2 BR 112019000282 A2 BR112019000282 A2 BR 112019000282A2 BR 112019000282 A BR112019000282 A BR 112019000282A BR 112019000282 A2 BR112019000282 A2 BR 112019000282A2
Authority
BR
Brazil
Prior art keywords
dosage form
quick release
outer coating
release outer
oral dosage
Prior art date
Application number
BR112019000282-0A
Other languages
English (en)
Inventor
Joseph Pulford Christopher
Original Assignee
Glaxosmithkline Consumer Healthcare Holdings
Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Consumer Healthcare Holdings, Llc filed Critical Glaxosmithkline Consumer Healthcare Holdings
Publication of BR112019000282A2 publication Critical patent/BR112019000282A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

aspectos da presente invenção são dirigidos a uma forma de dosagem oral compreendendo um núcleo contendo um ou mais ingredientes ativos e um revestimento exterior de liberação rápida. o revestimento exterior de liberação rápida inclui um polímero solúvel em água; um sacarídeo ou álcool de açúcar, ou uma combinação destes, e um flavorizante. o flavorizante pode ser uma sensação de aquecimento que é liberada na cavidade oral do usuário depois de inserir a forma de dosagem na sua boca.
BR112019000282-0A 2016-07-05 2017-07-05 forma de dosagem oral contendo um revestimento exterior de liberação rápida BR112019000282A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358223P 2016-07-05 2016-07-05
US62/358,223 2016-07-05
PCT/US2017/040655 WO2018009500A1 (en) 2016-07-05 2017-07-05 Oral dosage form containing a fast release exterior coating

Publications (1)

Publication Number Publication Date
BR112019000282A2 true BR112019000282A2 (pt) 2019-04-16

Family

ID=60892480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000282-0A BR112019000282A2 (pt) 2016-07-05 2017-07-05 forma de dosagem oral contendo um revestimento exterior de liberação rápida

Country Status (8)

Country Link
US (1) US11433037B2 (pt)
EP (1) EP3481379A4 (pt)
JP (1) JP2019524709A (pt)
CN (1) CN109562075A (pt)
BR (1) BR112019000282A2 (pt)
CA (1) CA3029985A1 (pt)
MX (1) MX2019000219A (pt)
WO (1) WO2018009500A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789546A (en) 1987-02-19 1988-12-06 Consumer Products Corp. Multiple-layer tablet with contrasting organoleptic characteristics
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
AU1655595A (en) * 1994-04-29 1995-11-09 Mcneil-Ppc, Inc. Solid pharmaceutical dosage form containing flavored film coating
JPH11508593A (ja) 1995-07-05 1999-07-27 ザ、プロクター、エンド、ギャンブル、カンパニー 加温化合物
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
GB9707978D0 (en) 1997-04-21 1997-06-11 Procter & Gamble Throat soothing compositions
GB9707979D0 (en) 1997-04-21 1997-06-11 Procter & Gamble Confectionery compositions
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
GB2350046B (en) 1999-05-20 2002-12-18 British Sugar Plc Edible compositions containing trehalose
DE19962251A1 (de) 1999-12-22 2001-09-06 Hermes Fabrik Pharm Praeparate Lutschtablette
US6780443B1 (en) 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
US6365215B1 (en) 2000-11-09 2002-04-02 International Flavors & Fragrances Inc. Oral sensory perception-affecting compositions containing dimethyl sulfoxide, complexes thereof and salts thereof
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
FR2832632B1 (fr) 2001-11-26 2004-04-23 Mane Fils V Capsule a solubilisation et liberation du contenu rapides
WO2004026308A1 (fr) 2002-09-21 2004-04-01 Shuyi Zhang Compose d'acetamidophenol et de tramadol a liberation prolongee
MX2007001611A (es) 2004-08-11 2007-04-10 Cadbury Adams Usa Llc Composiciones calidas y sistemas de liberacion de las mismas.
CN101262852A (zh) * 2004-12-13 2008-09-10 麦克内尔-Ppc股份有限公司 稳定活性药物成分的组合物和方法
US20070275135A1 (en) 2005-02-09 2007-11-29 First Flavor, Inc. Taste sampling process and product
US20050196517A1 (en) 2005-02-14 2005-09-08 Mars, Incorporated Edible product having discrete regions with different heats of solution
BRPI0609763A8 (pt) 2005-04-15 2017-11-21 Firmenich & Cie Composição de sensação na pele e de flavor, uso da mesma, e, produto alimentício, produto de cuidado oral, produto de cuidado corporal ou produto farmacêutico
WO2006136196A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
ES2478634T3 (es) 2005-12-23 2014-07-22 Intercontinental Great Brands Llc Composiciones que proporcionan sensación de calor para administración oral o dérmica
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
CA2708152A1 (en) * 2007-12-10 2009-06-18 Eurand, Inc Orally disintegrating tablets comprising diphenhydramine
ES2425356T3 (es) 2008-04-15 2013-10-14 Firmenich S.A. Composición sensorial de calidez
CN101612144A (zh) * 2008-05-19 2009-12-30 张书毅 含对乙酰氨基酚和曲马多的缓释制剂
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
CN102470111A (zh) * 2009-06-29 2012-05-23 麦克内尔-Ppc股份有限公司 含充液胶囊的药物片剂
BR112012010170A2 (pt) 2009-10-28 2016-04-12 Mcneil Ppc Inc composições de revestimento para desintegração/dissolução rápida
EP2588200B1 (en) 2010-06-30 2018-02-28 Colgate-Palmolive Company Multilayer films for delivery of flavor
MX357636B (es) 2011-02-14 2018-07-17 Procter & Gamble Formas de dosificacion solidas que comprenden miel en el recubrimiento.
CA2834231A1 (en) 2011-04-28 2012-11-01 Acme Specialty Products, Llc Taste masking compositions and edible forms thereof
US20130177646A1 (en) 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US20140010768A1 (en) 2012-07-09 2014-01-09 Wild Flavors, Inc. Flavoring ingredient in oral compositions
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine

Also Published As

Publication number Publication date
JP2019524709A (ja) 2019-09-05
CA3029985A1 (en) 2018-01-11
EP3481379A1 (en) 2019-05-15
RU2019102920A3 (pt) 2020-08-28
WO2018009500A1 (en) 2018-01-11
EP3481379A4 (en) 2020-03-11
US20180008562A1 (en) 2018-01-11
US11433037B2 (en) 2022-09-06
MX2019000219A (es) 2019-09-04
RU2019102920A (ru) 2020-08-06
CN109562075A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
MX2021006035A (es) Formulaciones cannabinoides estables.
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
MX2017012877A (es) Composiciones gomosas de multicomponentes con nucleo suave.
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
BR112018014545A2 (pt) probióticos para uso como agentes anti-inflamatórios na cavidade oral
BR112016002251A2 (pt) dispositivo para administração de fármacos
CO6541583A2 (es) Microcapsulas de fexofenadina y composiciones que las contienen
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
BR112018068642A2 (pt) composição e uso de composição
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
CL2012001940A1 (es) Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple.
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos
BR112014025990A2 (pt) preparação e método para a profilaxia e tratamento de osteoporose atípica
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
BR112019000282A2 (pt) forma de dosagem oral contendo um revestimento exterior de liberação rápida
BR112016002074A2 (pt) forma de dosagem de película oral instantaneamente molhável sem tensoativo ou poli-álcool
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
BR112019023827A2 (pt) composições que compreendem óleos essenciais
WO2013098268A3 (en) Tablets and dry-coated agents
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]